We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gen-Probe Acquires GTI Diagnostics for USD 53 Million

By LabMedica International staff writers
Posted on 23 Jan 2012
Gen-Probe (San Diego, CA, USA) has acquired GTI Diagnostics (Waukesha, WI, USA) for USD 53 million in cash. The acquisition strengthens Gen-Probe's transplant diagnostics business, providing new growth opportunities in blood bank and specialty coagulation markets.

GTI Diagnostics is a privately held specialty diagnostics company focused on the transplantation, blood bank, and specialty coagulation markets. Gen-Probe acquired GTI from the Riverside Company, a global private equity firm, and from individual investors who include the company's founders and management.

GTI develops and manufactures the human leukocyte antigen (HLA) antibody detection products sold by Gen-Probe under its Lifecodes brand. GTI also commercializes a number of other HLA-related testing products, including serological typing trays, enzyme immunoassays (EIAs), and a range of molecular typing products for donor-recipient matching and patient monitoring.

In the specialty coagulation market, GTI sells immunoassay products that measure a patient's immune response to heparin and Factor VIII therapies. The blood bank product line includes immunoassay products that measure antibodies developed against transfused platelets.

Gen-Probe Inc. develops, manufactures, and markets rapid, accurate, and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.

Related Links:
Gen-Probe
GTI Diagnostics

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more